These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 391261)

  • 21. Pemphigus and pemphigoid: dermatologic examples of type II immune reactivity.
    Sams WM
    Ann Allergy; 1976 Oct; 37(4):255-63. PubMed ID: 791025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pemphigus foliaceus preceded by pemphigoid in a patient with thymoma: coincidence or pathogenetic relationship?].
    Lutowiecka-Wranicz A; Sysa-Jedrzejowska A; Bartkowiak B; Waszczykowska E; Chorzelski T
    Przegl Dermatol; 1987; 74(6):460-2. PubMed ID: 3330249
    [No Abstract]   [Full Text] [Related]  

  • 23. [Therapeutic experience in pemphigus and pemphigoid].
    Aloi FG; Pippione M
    G Ital Dermatol Venereol; 1984; 119(5):357-64. PubMed ID: 6392076
    [No Abstract]   [Full Text] [Related]  

  • 24. Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment.
    Kartan S; Shi VY; Clark AK; Chan LS
    Am J Clin Dermatol; 2017 Feb; 18(1):105-126. PubMed ID: 27878477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practice and Educational Gaps in Blistering Disease.
    Ehsani-Chimeh N; Marinkovich MP
    Dermatol Clin; 2016 Jul; 34(3):251-6. PubMed ID: 27363880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunopathology of pemphigus vulgaris, bullous pemphigoid and related bullous dermatoses.
    Patel HP; Anhalt GJ; Provost TT; Diaz LA
    Clin Immunol Rev; 1983-1984; 2(2):157-86. PubMed ID: 6370527
    [No Abstract]   [Full Text] [Related]  

  • 27. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases.
    Stanley JR
    J Clin Invest; 1989 May; 83(5):1443-8. PubMed ID: 2651476
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of cyclosporin on bullous pemphigoid and pemphigus.
    Thivolet J; Barthelemy H; Rigot-Muller G; Bendelac A
    Lancet; 1985 Feb; 1(8424):334-5. PubMed ID: 2857378
    [No Abstract]   [Full Text] [Related]  

  • 29. Combined features of pemphigus and pemphigoid induced by penicillamine.
    Velthuis PJ; Hendrikse JC; Nefkens JJ
    Br J Dermatol; 1985 May; 112(5):615-9. PubMed ID: 3890920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kaposi varicelliform eruption in patients with autoimmune bullous dermatoses.
    Lehman JS; el-Azhary RA
    Int J Dermatol; 2016 Mar; 55(3):e136-40. PubMed ID: 26500144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bullous autoimmune skin disease in the dog: (2) immunopathological assessment.
    Bennett D; Lauder IM; Kirkham D; McQueen A
    Vet Rec; 1980 Jun; 106(25):523-5. PubMed ID: 7001727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bullous dermatoses with special reference to the symptomatology of the eyelids in pemphigus vulgaris].
    Lisch K
    Klin Monbl Augenheilkd; 1983 Dec; 183(6):493-6. PubMed ID: 6366347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of IgG subclasses and complement binding activity of autoantibodies from patients with bullous pemphigoid and pemphigus.
    Brooks WS; Lee YY; Abell E; Deng JS
    J Clin Lab Anal; 1989; 3(5):307-11. PubMed ID: 2681622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin.
    Nagata Y; Karashima T; Watt FM; Salmhofer W; Kanzaki T; Hashimoto T
    J Invest Dermatol; 2001 Apr; 116(4):556-63. PubMed ID: 11286623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoadsorption in dermatology.
    Meyersburg D; Schmidt E; Kasperkiewicz M; Zillikens D
    Ther Apher Dial; 2012 Aug; 16(4):311-20. PubMed ID: 22817118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoimmune bullous skin diseases. Part 1: Clinical manifestations.
    Kneisel A; Hertl M
    J Dtsch Dermatol Ges; 2011 Oct; 9(10):844-56; quiz 857. PubMed ID: 21955378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Application of the biotin-avidin system to the study of autoimmune bullous diseases: immunofluorescence method using biotinylated-pemphigus and -pemphigoid antibodies and fluoresceinated avidin].
    Muramatsu T; Sakamoto K; Ikeda S
    Nihon Hifuka Gakkai Zasshi; 1988 Sep; 98(10):977-80. PubMed ID: 3065537
    [No Abstract]   [Full Text] [Related]  

  • 38. [Analysis of infiltrating cells in the lesional skin of the autoimmune diseases-pemphigus, pemphigoid, and lupus erythematosus].
    Hayakawa K
    Nihon Hifuka Gakkai Zasshi; 1988 Sep; 98(10):1023-8. PubMed ID: 3065535
    [No Abstract]   [Full Text] [Related]  

  • 39. Factors responsible for death in patients with pemphigus.
    Kanwar AJ; Dhar S
    J Dermatol; 1994 Sep; 21(9):655-9. PubMed ID: 7962969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International mortality from bullous diseases since 1950.
    Savin JA
    Br J Dermatol; 1976 Feb; 94(2):179-89. PubMed ID: 766815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.